By Iain Gilbert
Date: Friday 03 May 2024
(Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.
By Josh White
Date: Monday 22 Apr 2024
(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.
By Iain Gilbert
Date: Thursday 04 Jan 2024
(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.
Currency | UK Pounds |
Share Price | 19.50p |
Change Today | -1.75p |
% Change | -8.24 % |
52 Week High | 31.40 |
52 Week Low | 9.25 |
Volume | 1,883,121 |
Shares Issued | 260.58m |
Market Cap | £50.81m |
RiskGrade | 312 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:29 | 10,000 @ 19.53p |
16:27 | 24,860 @ 19.53p |
16:17 | 6,233 @ 19.53p |
16:15 | 5,490 @ 19.80p |
16:09 | 5,141 @ 19.53p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research